🇺🇸 FDA
Pipeline program

11C-SB207145, 11C-DASB

C24-41

Phase 3 small_molecule active

Quick answer

11C-SB207145, 11C-DASB for Parkinson's disease, Prodromal phase of Parkinson's disease is a Phase 3 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Parkinson's disease, Prodromal phase of Parkinson's disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials